Featured Research Search Results
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
Clinicaltrials.gov identifier:
NCT04251052
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Phase 1
Pancreatic Cancer Screening Study (CAPS5)
Clinicaltrials.gov identifier:
NCT02000089
Prevention
Screening study for people at high risk for pancreatic cancer
Phase 3
Registry for People at Increased Risk for Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT06151223
Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04090567
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
Phase 2
PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
Clinicaltrials.gov identifier:
NCT04472338
Prevention
Screening study for people with a mutation linked to prostate cancer risk
The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations
Surveys, Registries, Interviews
Study for people who have a BRCA1, BRCA2, or PALB2 genetic mutation
Screening Study for Men at High Genetic Risk for Prostate Cancer
Clinicaltrials.gov identifier:
NCT03805919
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Clinicaltrials.gov identifier:
NCT05806515
Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation
Phase 2
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Pancreatic Cancer Early Detection for People at High Risk
Clinicaltrials.gov identifier:
NCT04970056
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
Clinicaltrials.gov identifier:
NCT03729115
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy
Clinicaltrials.gov identifier:
NCT05287451
Prevention
Prevention study for women at high risk for ovarian cancer
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation
Phase 2
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
Clinicaltrials.gov identifier:
NCT05129605
Prevention
People at high risk for prostate cancer due to an inherited mutation
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Phase 2
Blood Markers of Early Pancreas Cancer
Clinicaltrials.gov identifier:
NCT03568630
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
Phase 1